4.6 Review

Musashi-1-A Stemness RBP for Cancer Therapy?

期刊

BIOLOGY-BASEL
卷 10, 期 5, 页码 -

出版社

MDPI
DOI: 10.3390/biology10050407

关键词

RNA– binding protein; musashi– 1; MSI1; stemness; cancer; cell cycle; signaling

类别

资金

  1. Wilhelm-Roux Program (Martin Luther University Halle/Wittenberg)
  2. EU
  3. DFG [GRK1591]

向作者/读者索取更多资源

The RNA-binding protein Musashi-1 (MSI1) plays a crucial role in promoting stemness properties during development and in cancer, contributing to cancer growth and therapy resistance. MSI1's specific expression pattern and diverse functions make it an interesting target for future cancer therapy, with current research focusing on MSI1-directed inhibitors with anti-tumor activity.
Simple Summary Musashi-1 (MSI1) is an RNA-binding protein that promotes stemness properties. It was initially discovered as a regulator of neuronal development and oocyte maturation in flies and frogs. Due to its specific expression pattern with high levels during development and in a variety of cancers, MSI1 evolved as an interesting target for cancer therapy. In cancer cells, the protein mainly promotes an undifferentiated state enhancing cancer growth and therapy resistance. In this review, we summarize previous findings from development of other organisms, outline MSI1 ' s expression and function in different cancer entities and highlight the development of MSI1-directed inhibitors. The RNA-binding protein Musashi-1 (MSI1) promotes stemness during development and cancer. By controlling target mRNA turnover and translation, MSI1 is implicated in the regulation of cancer hallmarks such as cell cycle or Notch signaling. Thereby, the protein enhanced cancer growth and therapy resistance to standard regimes. Due to its specific expression pattern and diverse functions, MSI1 represents an interesting target for cancer therapy in the future. In this review we summarize previous findings on MSI1 ' s implications in developmental processes of other organisms. We revisit MSI1 ' s expression in a set of solid cancers, describe mechanistic details and implications in MSI1 associated cancer hallmark pathways and highlight current research in drug development identifying the first MSI1-directed inhibitors with anti-tumor activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据